The largest community of pharma leaders

Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience

Objective

According to the manufacturer’s documentation, rituximab (RTX) should be administered with slow infusion rates to prevent infusion-related adverse events (AEs). Nevertheless, slow infusions are time-consuming and uncomfortable for patients and medical staff. Therefore, faster infusion rates have been studied and proven safe and well tolerated in lymphomas and rheumatoid arthritis (RA). A small amount of data is available for rapid RTX infusions in non-RA autoimmune diseases.


Methods

Beginning in September 2015, all RTX-reated patients in our centre and willing to participate, were switched from slow RTX infusions (4.25 hours, given at least once to all patients) to fast infusions (2 hours). A total of 85 RTX 2-hour infusions was administered to 53 patients with autoimmune diseases with renal involvement and selected primary glomerulonephritides (26 ANCA-associated vasculitis, nine systemic lupus erythematodes, seven membranous nephropathy, five IgM nephropathy and six other autoimmune disease). Most of the patients received chronic corticosteroid therapy. The prednisone equivalent dose median (IQR) was 0.1 (0.0–0.2) mg/kg/day.


Results

Rapid RTX infusions were generally well tolerated. Only two infusion-related AEs were recorded: one Common Terminology Criteria for Adverse Events, grade 3, (lower back pain and hypotension followed by chills necessitating methylprednisolone and dipyrone administration) and one grade 1 (subjective intolerance). The AEs frequency does not differ from other studies with rapid RTX infusions in patients with lymphomas and RA.


Conclusions

Our experience supported other published data and provides evidence concerning the safety of non-initial RTX 2-hour infusion which can be administered without raising the infusion-related AEs rate in patients with kidney-affecting autoimmune diseases and glomerulonephritides.

http://ejhp.bmj.com/cgi/content/short/26/4/210?rss=1

Recent Articles

Sperm Bank Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Androcryos and Cryos International-Denmark ApS | Technavio

LONDON--(BUSINESS WIRE)-- #GlobalSpermBankMarket--The Global Sperm Bank Market will grow by $...

Global Hereditary Transthyretin Amyloidosis (hATTR) Competitive Landscape, Market Insights, Epidemiology and Forecast 2017-2020 & 2030 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hereditary Transthyretin Amyloidosis (hATTR) - Competitive Landscape, Market Insights,...

Strive Health Welcomes David Thornton as Chief People Officer

DENVER--(BUSINESS WIRE)-- #executiveteam--Leading specialized kidney care company Strive Health today announced...

Accenture Puts Data Science to Work for Pediatric Leukemia Research

NEW YORK--(BUSINESS WIRE)--Accenture has built a data and analytics approach to...

FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--MultiStem is the only cell therapy program for...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.